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The synthesis and characterization of two new sets of arylsulfonehydrazone benzenesulfonamides (4a-4i
with phenyl tail and 4j-4q with tolyl tail) are reported. The compounds were designed according to a
dual-tails approach to modulate the interactions of the ligands portions at the outer rim of both hy-
drophobic and hydrophilic active site halves of human isoforms of carbonic anhydrase (CA, EC 4.2.1.1).
The synthesized sulfonamides were evaluated in vitro for their inhibitory activity against the following
human (h) isoforms, hCA I, II, IV and IX. With the latter being a validated anticancer drug target and a
marker of tumor hypoxia, attractive results arose from the Compounds' inhibitory screening in terms of
potency and selectivity. Indeed, whereas the first subset of compounds 4a-4i exhibited great efficacy in
inhibiting both the ubiquitous, off-target hCA II (KIs 9.5e172.0 nM) and hCA IX (KIs 7.5e131.5 nM), the
second subset of tolyl-bearing derivatives 4j-4q were shown to possess a selective hCA IX inhibitory
action over isoforms I, II and IV. The most selective compounds 4l and 4nwere further screened for their
in vitro cytotoxic activity against MCF-7 and MDA-MB-231 cancer cell lines under hypoxic conditions. The
selective IX/II inhibitory trend of 4j-4q compared to those of compounds 4a-4i was unveiled by docking
studies. Further exploration of these molecules could be useful for the development of novel antitumor
agents with a selective CA inhibitory mechanism.
© 2018 Elsevier Masson SAS. All rights reserved.1. Introduction
Human carbonic anhydrase (CA, EC 4.2.1.1) IX is a membrane-
bound enzyme whose expression is strongly induced by hypoxia,. Ibrahim), claudiu.supuran@
served.a condition featured by low level of oxygen occurring in different
types of solid tumors, such as glioma, breast cancer and colon
carcinoma [1e3]. The activity of the over-expressed hCA IX main-
tains a proper external pH, supporting an acidic extracellular
microenvironment suited for hypoxic tumor cells, thus regulating
cell proliferation, adhesion, and malignant cell invasion [1]. hCA IX
inhibition has been shown to be associated with a significant
suppression of the growth of both primary tumors and metastases,
recognizing such an isozyme as a validated anticancer drug target,
marker of tumor hypoxia and prognostic factor for several types of
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hCA IX has become an attractive target for the design of anti-
neoplastic drugs [6]. Despite that acetazolamide (AAZ) and other
sulfonamide CAIs were reported to slowdown tumor growth and to
delay tumor development, the lack of selectivity of sulfonamide-
like CAIs against the different human (h) isozymes is the main
issue that prevents a wider pharmaceutical application to date
[1,7,8]. Typically, the sulfonamide moiety coordinates the Zn ion
present within the hCAs active sites and establishes two additional
hydrogen bonds with a residue nearby (Thr199). Such binding
features are common among the active site architectures of all the
15 human isozymes,1 which belong to the a-class (seven distinct
genetic families have been identified so far, the a-, b-, g-, d-, z-. h-
and q-CAs) [8,9]. The active site cavity of hCAs is divided into two
very different environments: the first one is delimited by a cluster
of hydrophobic amino acids, whereas the other one is lined with
hydrophilic residues (Fig. 1) [8,9].
Different approaches have been employed to design sulfon-
amide CAIs that exceed the poor selectivity boundary, with the “tail
approach" being the most efficient and exploited one (Fig. 1)
[4,10,11]. It consists in appending different molecular moieties
(tails) to the aromatic/heterocyclic ring bearing the zinc binding
group, in order to modulate the interactionwith themiddle and the
rim parts of the active site cavity, which is the most variable region
among the 15 isoforms mentioned above. In this context, a ureido-
tailed sulfonamide CAI (SLC-0111) successfully completed Phase I
clinical trials for the treatment of advanced, metastatic hypoxic
tumors over-expressing hCA IX, being scheduled for Phase II trials
later last year [4,12].
In the present work, we apply a dual-tails approach to modulate
the interactions of the ligands at the outer rim of both hydrophobic
and hydrophilic regions, seeking for isoform-selective inhibition
profiles. Dual-tails CAIs were previously reported by Tanpure et al.
by applying the “Click approach” to combine glyosidic and phenyl
portions onto a sulfonamide scaffold [13].
The herein designed compounds 4a-q possess a Zinc Binding
Group (ZBG) of the benzenesulfonamide type and a highly flex-
ible molecular structure of the methyl hydrazone type to
enhance the probability of a proper orientation and contacts with
both hydrophilic and hydrophobic halves of the active site. A
sulfone group was incorporated to increase the binding to the
hydrophilic part of the active site. The aromatic tail appended at
the sulfone moiety is of the phenyl or tolyl type as shown in
Fig. 1. On the other hand, the use of diverse hydrophobic sub-
stituents on the hydrazine-linked aromatic portion should
ensure suited SAR exploration regarding the hydrophobic region.
All of these designed compounds were synthesized, character-
ized and biologically tested against four relevant hCA isoforms (I,
II, IV and IX). Furthermore, compounds with best hCA IXFig. 1. Design approach to arylsulfone-binhibition properties have been subjected to cytotoxic activity
evaluation against two different cell lines expressing the tumor-
associated isozyme.
2. Results and discussion
2.1. Chemistry
To obtain the target compounds 4a-q, variable 2-bromoacetyl
aryl or heteroaryl derivatives (2a-k) were refluxed separately
with sodium benzene sulfinate in ethanol obtaining different
phenyl sulfones 3a-q [14]. Consequently, the intermediate com-
pounds 3a-q were refluxed with 4-hydrazinobenzene sulfonamide
HCl salt in ethanol and catalytic amount of acetic acid to afford the
hydrazones 4a-q (Scheme 1). 1H NMR of compounds 4a-q revealed
the two protons of the active methylene group (-SO2CH2-) which
appeared as singlet at nearly d¼ 5.01 ppm. In addition, 13C NMR
confirmed this data by illustrating a peak for this carbon (-SO2CH2-)
at about d¼ 54.3 ppm. Peaks of D2O exchangeable protons were
important in this analysis to confirm that the reaction was com-
plete. 1H NMR analysis of compound 4i was very interesting as it
informed us that this compound presented in Z and E isomers by
ratio (2:1) when this compoundwas dissolved in DMSO. Otherwise,
all the synthesized compounds were expected to be found in one
conformer in solid state, which is Z conformer analogous to the
reported compounds [15e17].
2.2. Biological evaluation
2.2.1. Carbonic anhydrase inhibition
The CA inhibitory properties of sulfonamide derivatives 4a-4q
against human isoforms CA I, II, IV and IX were measured using
acetazolamide (AAZ) as standard inhibitor by a stopped flow CO2
hydrase assay [18]. The rational for the choice of these four isoforms
is that the ubiquitous hCA I and II are the main off-target isoforms
for the anticancer CAIs therapeutic application. Isoform hCA IV
shares with hCA IX the extra-cellular localization and is a drug
target for retinitis pigmentosa, stroke and inflammatory pathol-
ogies such as rheumatoid arthritis.
The following structure-activity relationship (SAR) were ob-
tained from the inhibition data reported in Table 1:
(i) The off-target isoform hCA I was moderately inhibited by
sulfonamides 4a-4q herein reported with inhibition con-
stants (KIs) spanning in the high nanomolar-low micromolar
range, between 272.1 and 3771.1 nM. Noteworthy, increasing
steric hindrance on the hydrazone aromatic portion almost
generally worsened the hCA I inhibitory efficacy of the re-
ported series of dual-tails sulfonamides. As a matter of fact,ased benzenesulfonamides (4a-4q).
Scheme 1. Synthetic scheme for compounds 4a-p. Reagents and conditions: (i) EtOH/reflux for 6 h; (ii) 4-NH2NHC6H5SO2NH2.HCl/EtOH/CH3COOH/reflux for 1 h.
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4o-4p arose as the least hCA I inhibitors herein reported with
KIs in the range 1924.4e3771.1 nM).
(ii) The physiologically dominant isoform hCA II was interest-
ingly inhibited by the investigated compounds with KI values
ranging between 9.5 and 791.1 nM. Indeed, despite the
generally efficient hCA II inhibitory efficiency ascribable to
4a-4q, an attractive trend can be deduced analyzing the data
in Table 1. The incorporation of the methyl group in the para
position of the sulfone-linked phenyl ring reduce the inhib-
itory efficacy of each tolyl derivative (KIs 9.5e172.0 nM) in
comparison to the unsubstituted analogue (KIs
199.6e791.1 nM) seven-to twentyone-fold. Of note, the best
hCA II inhibitory activity was ascribed to the p-F derivative
4a, with this latter being as potent as the standard AAZ.
(iii) Themembrane-associated hCA IVwas the least one inhibited
by the dual-tails inhibitors herein reported, with KIs span-
ning in the low micromolar range (KIs 709.5e4166.8 nM).
Incorporation of the nitro group on the hydrazone-aromatic
portion (4e and 4o) or the substitution of this latter with aheterocycle of the furan (4h) or thiophene (4q) type
heightened the relative compounds potency to a sub-
micromolar range (709.5e912.0 nM).
(iv) The target tumor-associated isoform hCA IX was undeniably
the most affected one amongst those herein considered.
Considering the inhibition trend arose for isoform II, it
immediately stands out from the inhibition data reported in
Table 1, that all reported sulfonamides inhibit the trans-
membrane isoform in the low-nanomolar (KIs spanning in
the range 5.3e131.5 nM), independently from the presence
of a methyl group on the sulfone-linked phenyl ring. As a
result, it could be hypothesized the likely presence of a
pocket in hCA IX binding cavity, which can accommodate the
methyl group, with unfavorable interactions conversely
taking place within the hCA II active site. Noteworthy, the p-
Cl, p-CH3 and 2-naphthyl derivatives (4l, 4n and 4p) within
the methyl substituted subset acted as the most potent hCA
IX inhibitors (KIs spanning in the range 5.3e15.3 nM) as well
as the p-F derivative 4a devoid of the methyl group (KI of
7.5 nM).
Table 1
Inhibition data of human CA isoforms hCA I, II, IV and IX with sulfonamides 4a-4q reported here and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow
CO2 hydrase assay [18].
Compound KI (nM)a SIb
hCA I hCA II hCA IV hCA IX (hCA I/IX) (hCA II/IX) (hCA IV/IX)
4a 272.1 9.5 1692.1 7.5 36.28 1.27 225.61
4b 517.5 48.6 2577.4 34.8 14.87 1.40 74.06
4c 894.2 53.3 2255.5 61.2 14.61 0.87 36.85
4d 747.3 38.9 2813.9 36.5 20.47 1.07 77.09
4e 1924.4 59.7 912.0 71.6 26.88 0.83 12.74
4f 3133.7 172.0 4166.8 131.5 23.83 1.31 31.69
4g 2847.2 65.7 3122.9 39.3 72.45 1.67 79.46
4h 574.0 91.6 709.5 79.3 7.24 1.16 8.95
4i 941.9 74.2 2887.8 69.1 13.63 1.07 41.79
4j 567.6 234.0 3510.9 39.5 14.37 5.92 88.88
4k 671.8 199.6 1350.2 27.6 24.34 7.23 48.92
4l 426.2 330.7 2009.2 8.7 48.99 38.01 230.94
4m 915.7 354.8 2296.0 56.1 16.32 6.32 40.93
4n 343.4 337.8 2721.6 5.3 64.79 63.74 513.51
4o 2273.7 791.1 795.0 79.2 28.71 9.99 10.04
4p 3771.1 431.0 2646.9 15.3 246.48 28.17 173.00
4q 905.6 291.8 839.2 56.3 16.09 5.18 14.91
AAZ 250 12 74 25 10.00 0.48 2.96
a Mean from 3 different assays, by a stopped flow technique (errors were in the range of ± 5e10% of the reported values).
b Selectivity as determined by the ratio of KI for hCA I, II or IV relative to hCA IX.
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in Table 1, interesting selectivity index (SI) arose for many
derivatives herein reported. Indeed, all the tested com-
pounds exhibited interesting selectivity towards hCA IX over
hCA I, with compound 4p showing the higher I/IX selectivity
herein reported with SI of 246.48. The results for all the
tested compounds illustrated great selectivity against hCA IX
over hCA IV, specially compounds 4a, 4l, 4n and 4p, dis-
playing SI of 225.61, 230.94, 513.51 and 173.00, respectively.
Finally, the methyl-devoid compounds displayed weak
selectivity for hCA IX and over hCA II, whereas the SI mark-
edly increased for the methyl-bearing subset, with com-
pounds 4l and 4n possessing an interesting selectivity with
SI 38.01 and 63.74, respectively (Table 1).2.2.2. In vitro cytotoxic assay
The p-Cl and p-CH3-bearing compounds 4l and 4n within the
tolyl-derivatives subset were further screened for their in vitro
cytotoxic activity, owing to their unique potency and selectivity
against the tumor-associated isoform hCA IX. Due to the recognized
expression of the latter in breast malignancies [19,20], these com-
pounds were screened against human breast adenocarcinoma cell
line (MCF-7) and triple negative breast cancer cell line (MDA-MB-
231) using doxorubicin as a reference drug. The assay was run
under hypoxic conditions of 5% CO2 at 37 C and the IC50 values in
mM conc. of both compounds relative to doxorubicin is presented in
Table 2. The results of the in vitro screening reported in Table 2
revealed that both compounds generally exhibited betterTable 2
IC50 values in mM of the in vitro cytotoxic inhibitory assay of compounds 4l and 4n
under hypoxic conditions (5% CO2) against MDA-MB-231 and MCF7 cell lines
compared to doxorubicin.
Compound IC50 (mM) (5% CO2)
MDA-MB-231 MCF7
4l 18.22± 1.26 3.9± 0.21
4n 5.14± 0.31 2.33± 0.14
Doxorubicin 0.44± 0.008 0.37± 0.02cytotoxic activity against (MCF7) cell line than (MDA-MB-231).
Compound 4n, incorporating a dual-tolyl group in both tails, dis-
played better activity than the p-Cl derivative 4l, with its activity
being the half of that displayed by the reference drug doxorubicin.3. Molecular docking studies
The binding modes of the herein reported compounds within
the CA isozymes II and IX (PDB 5LJT [21] and 5FL4 [22], respectively;
hCA IX residues are reported in brackets), were explored by docking
and MM-GBSA simulations to unveil the relationships between
structural features and the inhibition profiles. As expected by the
in vitro results, in all docking solutions the benzenesulfonamide
moiety is oriented deeply into the active sites of both the isoforms
engaging two hydrogen bonds with the hCA II Thr199 (hCA IX
Thr200). Its negatively charged nitrogen atom directly coordinated
the zinc ion and the hydrophobic region lined by Val121, Val143
and Leu198 (hCA IX Val121, Val142 and Leu199) accommodated the
phenyl ring. For all 4a-q derivatives, the tail appended at the ben-
zenesulfonamide was similarly oriented in the two isoform active
sites (Fig. 2). This orientation was primarily determined by the
three-center H-bond that the sulfone (SO2) moiety engaged with
the HE-Gln92 (HE-Gln92) and HD-Asn67 (HE-Gln71) atoms of the
“hydrophilic” region of both active sites. Such a set of interactions
strongly affected the positioning of the sulfone-linked aromatic
portion of the ligands within the region lined by Ile91 (Leu91),
Glu69 (Thr73) and Arg58 (Arg62), while the hydrazone aromatic
portions accommodated in a wide hydrophobic area defined by
Phe131, Val135, Leu204, Pro202, Pro201 and Leu198 (Val130, Leu
134, Ala205, Pro203, Pro202 and Leu199), with p-p and p-alkyl
interactions occurring between the aryl group and lipophilic side
chains.
A key role is played by the hCA II/IX Glu69/Thr73 mutation in
explaining the trend of inhibition profiles of derivatives 4a-4i and
4j-4q against trans-membrane hCA IX over the cytosolic hCA II
(Fig. 3). Indeed, in hCA IX the para methyl-substituent on the ter-
minal aromatic ring of 4j-4q is oriented towards Thr73, with lipo-
philic interactions stabilizing the pose. Moreover, the less bulky
Thr73 residue in hCA IX provides to the aromatic (un/)substituted
tails more space than the Glu69 in the hCA II. As a matter of fact, the
Fig. 2. (A) Superposed binding hypotheses of compounds 4g (red) and 4l (pink) within hCA II. (B) Detailed view of the hCA II binding area lined by Glu69 and Arg58 residues
(molecular surface in green). The molecular surfaces of 4g and 4l are shown and the compound structures represented in sticks (red and pink, respectively). (For interpretation of
the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3. (A) Superposed binding hypotheses of compounds 4g (red) and 4l (pink) within hCA IX. (B) Detailed view of the hCA IX binding area lined by Thr73 and Arg62 residues
(molecular surface in blue). The molecular surfaces of 4g and 4l are shown and the compound structures represented in sticks (red and pink, respectively). (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
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strains the position of the Glu69 and prevents an ideal shape
complementarity of the substituted derivatives thus explaining the
worst inhibition profile when compared with the unsubstitued
ones.
It is reasonable to ascribe the potent and IX/II selective efficacy
of compounds 4l, 4n and 4p (II/IX ratio of 38, 64 and 28) within the
p-methyl-substituted subset to most favorable interactions taking
place between the p-Cl, p-CH3 and 2-naphthyl moieties, respec-
tively, with the aforementioned lipophilic region of the tumor-
associated isoform IX (Fig. 3).4. Conclusion
In the present study, we reported the synthesis and character-
ization of two new series of arylsulfonehydrazone benzenesulfo-
namide (4a-4i and 4j-4q). The compounds were designed
according to a dual-tails approach to modulate the interactions of
the ligands portions at the outer rim of both hydrophobic and hy-
drophilic active site halves of varied hCAs. The in vitro evaluation of
the newly synthesized sulfonamides against hCA I, II, IV and IX
furnished interesting results in terms of compounds inhibitory
potency and selectivity. Indeed, whereas the first subset ofcompounds 4a-4i (unsubstituted phenyl-bearing) exhibited great
efficacy in inhibiting both the ubiquitous, off-target hCA II (KIs
9.5e172.0 nM) and hCA IX (KIs 7.5e131.5 nM), the tolyl-bearing
derivatives 4j-4q were shown to possess a selective hCA IX inhib-
itory action over isoforms I, II and IV. In vitro cytotoxic activity
evaluation of the most IX/II selective compounds 4l and 4n against
MCF-7 and MDA-MB-231 cell lines under hypoxic conditions
showed an efficient anti-proliferative action in the lowmicromolar
range, with compound 4n showing a two-fold reduced efficacy
than that shown by the reference drug doxorubicin. The study of
the derivatives binding mode by modelling studies performed for
all compoundswith hCA II and IX shed light on the five-to sixty-fold
II/IX selective inhibitory efficacy of 4j-4q.5. Experimental
5.1. Chemistry
5.1.1. General
Melting points were recorded on a Stuart SMP10 digital melting
point apparatus and were uncorrected. Infrared (IR) Spectra were
recorded as KBr disks using a Shimadzu FT-IR 8400S infrared
spectrophotometer. Mass spectral data are given as m/z (Intensity
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13C: 100MHz) spectrometer. 1H NMR spectra were run at 400MHz
and 13C spectra were run at 100MHz in deuterated dimethylsulf-
oxide (DMSO-d6). Chemical shifts are expressed in d values (ppm)
using the solvent peak as internal standard. All coupling constant
(J) values are given in hertz. The abbreviations used are as follows:
s, singlet; d, doublet; m, multiplet. Elemental analyses were carried
out at the Regional Center for Mycology and Biotechnology, Al-
Azhar University, Egypt. Reaction courses and product mixtures
were routinely monitored by Thin Layer Chromatography (TLC) on
silica gel precoated F254 Merck plates. Unless otherwise noted, all
solvents and reagents were commercially available and used
without further purification. The analytical data of compounds 3a-
q were found as reported [14,23e28].5.1.2. General procedure for the preparation of compounds 4a-q
To a solution of the appropriate 1-aryl or heteroaryl-substituted
2-(aryl sulfonyl) ethanone 3a-q (1mmol) in absolute ethanol in the
presence of catalytic amount of glacial acetic acid, 4-
hydrazinobenzenesulfonamide (0.187 g, 1mmol) was added. The
reaction mixture was heated under reflux. The solid formed was
collected by filtration, dried and recrystallized from ethanol/DMF to
afford compounds 4a-q.5.1.2.1. 4-[2-(1-(4-Fluorophenyl)-2-(phenylsulfonyl)ethylidene)
hydrazinyl] benzenesulfonamide (4a). White crystals, (yield 60%), m.
p. 251e252 C; IR (KBr, nmax/cm1): 3361, 3329, 3271 (NH2 & NH),
1340 and 1145 (SO2); 1H NMR (DMSO-d6) d ppm: 5.22 (s, 2H,
-SO2CH2-), 7.09 (m, 4H, Ar-H and D2O exchangable, -SO2NH2), 7.19
(d, J¼ 8.8 Hz, 2H, Ar-H), 7.51 (m, 1H, Ar-H), 7.59 (m, 2H, Ar-H), 7.67
(d, J¼ 8.8 Hz, 2H, Ar-H), 7.75 (t, J¼ 7.4 Hz, 2H, Ar-H), 7.85 (d,
J¼ 7.2 Hz, 2H, Ar-H), 10.08 (s, 1H, D2O exchangable, -NH); 13C NMR
(DMSO-d6) d ppm: 64.01 (-CH2-), 112.70, 115.45, 120.53, 123.19,
127.72, 128.64, 129.43, 131.86, 134.50, 135.2, 139.40, 147.53; Anal.
Calcd. for C20H18FN3O4S2 (447.50): C, 53.68; H, 4.05; N, 9.39; Found
C, 53.31; H, 4.23; N, 9.62.5.1.2.2. 4-[2-(1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethylidene)
hydrazinyl] benzenesulfonamide (4b). White crystals, (yield 77%), m.
p. 227e228 C; IR (KBr, nmax/cm1): 3360, 3325, 3263 (NH2 & NH),
1330 and 1149 (SO2); 1H NMR (DMSO-d6) d ppm: 5.21 (s, 2H, -
SO2CH2-), 7.14 (s, 2H, D2O exchangable, -SO2NH2), 7.20 (d,
J¼ 8.8 Hz, 2H, Ar-H), 7.34 (d, J¼ 8.7 Hz, 2H, Ar-H), 7.51 (t, J¼ 7.5 Hz,
2H, Ar-H), 7.59 (t, J¼ 7.5 Hz, 1H, Ar-H), 7.68 (d, J¼ 8.8 Hz, 2H, Ar-H),
7.74 (d, J¼ 8.7 Hz, 2H, Ar-H), 7.85 (d, J¼ 7.5 Hz, 2H, Ar-H), 10.14 (s,
1H, D2O exchangable, -NH); 13C NMR (DMSO-d6) d ppm: 52.19
(CH2), 112.81, 127.72, 128.21, 128.48, 128.65, 129.45, 131.43, 133.03,
134.52, 135.39, 136.53, 139.57, 147.49; Anal. Calcd. for
C20H18ClN3O4S2 (463.96): C, 51.77; H, 3.91; N, 9.06; Found C, 52.19;
H, 4.08; N, 8.87.5.1.2.3. 4-[2-(1-(4-Bromophenyl)-2-(phenylsulfonyl)ethylidene)
hydrazinyl] benzenesulfonamide (4c). White crystals, (yield 53%), m.
p. 243e244 C; IR (KBr, nmax/cm1): 3363, 3332, 3248 (NH2 & NH),
1342 and 1145 (SO2); 1H NMR (DMSO-d6) d ppm: 5.21 (s, 2H,
SO2CH2), 7.13 (s, 2H, D2O exchangable, -SO2NH2), 7.19 (d, J¼ 8.8 Hz,
2H, Ar-H), 7.48 (d, J¼ 8.6 Hz, 2H, Ar-H), 7.53 (d, J¼ 7.8 Hz, 2H, Ar-H),
7.61 (t, J¼ 7.3 Hz, 1H, Ar-H), 7.69 (dd, J¼ 2.3 Hz, J¼ 6.6 Hz, 4H, Ar-
H), 7.86 (d, J¼ 7.3 Hz, 2H, Ar-H), 10.14 (s, 1H, D2O exchangable,
-NH); 13C NMR (DMSO-d6) d ppm: 52.07 (CH2), 112.94, 121.94,
121.72, 128.34, 128.48, 129.60, 131.51, 134.55, 134.73, 136.57, 138.93,
147.47; Anal. Calcd. for C20H18BrN3O4S2 (508.41): C, 47.25; H, 3.57;
N, 8.27; Found C, 46.96; H, 3.74; N, 8.64.5.1.2.4. 4-[2-(2-(Phenylsulfonyl)-1-(p-tolyl)ethylidene)hydrazinyl]
benzenesulfonamide (4d). Light brown crystals, (yield 73%), m. p.
225e226 C; IR (KBr, nmax/cm1): 3363, 3321, 3267 (NH2 & NH),
1341 and 1149 (SO2); 1H NMR (DMSO-d6) d ppm: 2.30 (s, 3H, -CH3),
5.17 (s, 2H, - SO2CH2-), 7.11 (s, 2H, D2O exchangable, -SO2NH2), 7.18
(d, J¼ 8.7 Hz, 2H, Ar-H), 7.32 (d, J¼ 8.0 Hz, 2H, Ar-H), 7.61e7.68 (m,
3H, Ar-H), 7.73 (d, J¼ 7.4 Hz, 2H, Ar-H), 7.86 (d, J¼ 8.2 Hz, 2H, Ar-H),
7.90 (d, J¼ 7.3 Hz, 2H, Ar-H), 9.99 (s, 1H, D2O exchangable, -NH);
13C NMR (DMSO-d6) d ppm: 21.22 (CH3), 52.37 (CH2), 112.61,
126.50, 127.71, 128.62, 129.14, 129.40, 132.77, 134.44, 134.91, 134.96,
137.92, 139.71, 147.77; ESI MS m/z: 443 [M]þ, 444 [Mþ1]þ, 445
[Mþ2]þ; Anal. Calcd. for C21H21N3O4S2 (443.54): C, 56.87; H, 4.77;
N, 9.47; Found C, 57.14; H, 4.89; N, 9.70.
5.1.2.5. 4-[2-(1-(4-Nitrophenyl)-2-(phenylsulfonyl)ethylidene)hydra-
zinyl] benzenesulfonamide (4e). Yellow crystals, (yield 72%), m. p.
230e232 C; IR (KBr, nmax/cm1): 3379, 3313, 3271 (NH2 & NH),
1334 and 1153 (SO2); 1H NMR (DMSO-d6) d ppm: 5.32 (s, 2H,
SO2CH2), 7.18 (s, 2H, D2O exchangable, - SO2NH2), 7.29 (d, J¼ 8.6 Hz,
2H, Ar-H), 7.52 (t, J¼ 7.4 Hz, 2H, Ar-H), 7.60 (t, J¼ 7.3 Hz, 1H, Ar-H),
7.72 (d, J¼ 8.8 Hz, 2H, Ar-H), 7.87 (d, J¼ 7.4 Hz, 2H, Ar-H), 7.99 (d,
J¼ 9.0 Hz, 2H, Ar-H), 8.13 (d, J¼ 9.0 Hz, 2H, Ar-H), 10.48 (s, 1H, D2O
exchangable, -NH); 13C NMR (DMSO-d6) d ppm: 52.07 (CH2), 113.37,
123.68, 127.30, 127.49, 127.74, 128.72, 129.51, 130.30, 134.63, 136.22,
139.44, 144.05, 146.74, 147.04; Anal. Calcd. for C20H18N4O6S2
(474.51): C, 50.62; H, 3.82; N,11.81; Found C, 50.87; H, 4.01; N,12.17.
5.1.2.6. 4-[2-(1-([1,10-Biphenyl]-4-yl)-2(phenylsulfonyl)ethylidene)
hydrazinyl] benzenesulfonamide (4f). White crystals, (yield 70%), m.
p. 220e221 C; IR (KBr, nmax/cm1): 3383, 3325, 3271 (NH2 & NH),
1330 and 1145 (SO2); 1H NMR (DMSO-d6) d ppm: 5.27 (s, 2H,
-SO2CH2-), 7.03 (d, J¼ 8.7 Hz, 1H, Ar-H), 7.14 (s, 2H, D2O exchang-
able, - SO2NH2), 7.22 (t, J¼ 9.0 Hz, 2H, Ar-H), 7.38 (t, J¼ 7.3 Hz, 1H,
Ar-H), 7.47e7.59 (m, 4H, Ar-H), 7.61 (d, J¼ 8.5 Hz, 2H, Ar-H), 7.71 (t,
J¼ 9.0, 4H, Ar-H), 7.84 (d, J¼ 8.4 Hz, 2H, Ar-H), 7.90 (d, J¼ 7.2 Hz,
2H, Ar-H), 10.18 (s, 1H, D2O exchangable, -NH); 13C NMR (DMSO-d6)
d ppm: 52.30 (CH2), 110.09, 111.45, 112.42, 113.01, 113.74, 124.04,
127.26, 127.40, 127.70, 128.75, 129.44, 129.53, 134.12, 136.62, 139.44,
147.14, 148.87; ESI MS m/z: 521 [Mþ2]þ; Anal. Calcd. for
C26H23N3O4S2 (505.60): C, 61.76; H, 4.59; N, 8.31; Found C, 61.58; H,
4.72; N, 8.57.
5.1.2.7. 4-[2-(1-(Naphthalen-2-yl)-2-(phenylsulfonyl)ethylidene)
hydrazinyl] benzenesulfonamide (4g). White crystals, (yield 62%), m.
p. 230e231 C; IR (KBr, nmax/cm1): 3360, 3329, 3263 (NH2 & NH),
1334 and 1149 (SO2); 1H NMR (DMSO-d6) d ppm: 5.35 (s, 2H,
-SO2CH2-), 7.15 (s, 2H, D2O exchangable, - SO2NH2), 7.27 (d,
J¼ 8.7 Hz, 1H, Ar-H), 7.35 (s, 1H, Ar-H), 7.47e7.51 (m, 1H, Ar-H), 7.60
(d, J¼ 9.0 Hz, 1H, Ar-H), 7.63e7.67 (m, 2H, Ar-H), 7.70e7.72 (m, 2H,
Ar-H), 7.83 (d, J¼ 8.1 Hz, 1H, Ar-H), 7.90e7.95 (m, 3H, Ar-H), 8.00 (d,
J¼ 8.6 Hz, 1H, Ar-H), 8.08 (d, J¼ 7.5 Hz, 1H, Ar-H), 8.73 (s, 2H, Ar-H),
10.18 (s, 1H, D2O exchangable, -NH); 13C NMR (DMSO-d6) d ppm:
52.22 (CH2), 112.86, 124.08, 126.15, 126.73, 127.76, 127.99, 128.69,
128.77, 129.39, 132.50, 132.98, 133.15, 134.44, 134.94, 135.27, 139.68,
147.66; Anal. Calcd. for C24H21N3O4S2 (479.57): C, 60.11; H, 4.41; N,
8.76; Found C, 60.43; H, 4.57; N, 8.98.
5.1.2.8. 4-[2-(1-(Furan-2-yl)-2-(phenylsulfonyl)ethylidene)hydra-
zinyl] benzenesulfonamide (4h). Brown crystals, (yield 67%), m. p.
245e247 C; IR (KBr, nmax/cm1): 3367, 3325, 3275 (NH2 & NH),
1340 and 1145 (SO2); 1H NMR (DMSO-d6) d ppm: 5.04 (s, 2H, -
SO2CH2-), 6.88 (t, J¼ 4.2 Hz, 1H, furan- H), 7.10 (d, J¼ 8.7 Hz, 2H, Ar-
H), 7.12 (s, 2H, D2O exchangable, - SO2NH2), 7.35 (d, J¼ 4.8 Hz, 1H,
furan-H), 7.49e7.61 (m, 4H, Ar-H), 7.65 (d, J¼ 8.6 Hz, 2H, Ar-H), 7.86
(d, J¼ 7.3 Hz, 2H, Ar-H), 10.06 (s, 1H, D2O exchangable, -NH); 13C
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127.84, 128.53, 129.47, 129.64, 134.60, 135.15, 139.52, 143.43, 147.35;
Anal. Calcd. for C18H17N3O5S2 (419.47): C, 51.54; H, 4.08; N, 10.02;
Found C, 51.71; H, 3.89; N, 10.35.
5.1.2.9. 4-[2-(1-(Benzofuran-2-yl)-2-(phenylsulfonyl)ethylidene)
hydrazinyl] benzenesulfonamide (4i). White crystals, (yield 72%), m.
p. 244e246 C; IR (KBr, nmax/cm1): 3383, 3321, 3259 (NH2&NH),
1334 and 1153 (SO2); 1H NMR (DMSO-d6) d ppm: 4.81 & 5.17 (s, 2H,
-SO2CH2-, Z& E isomers), 6.97 (d, J¼ 8.7 Hz, 1H, Furan-H), 7.10e7.16
(m, 3H, Ar-H and D2O exchangable, - SO2NH2), 7.20e7.37 (m, 2H, Ar-
H), 7.50e7.65 (m, 3H, Ar-H), 7.72e7.76 (m, 3H, Ar-H), 7.87 (d,
J¼ 7.4 Hz, 2H, Ar-H), 7.92 (d, J¼ 6.2 Hz, 2H, Ar-H), 10.35 & 10.57 (s,
1H, D2O exchangable, -NH, Z & E isomers); 13C NMR (DMSO-d6)
d ppm: 52.39 (CH2), 112.76, 113.74, 126.73, 127.00, 127.13, 127.43,
127.71, 128.04, 128.70, 129.42, 129.47, 132.26, 134.44, 135.16, 136.66,
136.80, 139.72, 139.90, 140.01, 147.70, 148.86; Anal. Calcd. for
C22H19N3O5S2 (469.53): C, 56.28; H, 4.08; N, 8.95; Found C, 56.01; H,
4.19; N, 9.17.
5.1.2.10. 4-[2-(1-Phenyl-2-tosylethylidene)hydrazinyl]benzenesulfo-
namide (4j). Buff crystals, (yield 83%), m. p. 223e224 C; IR (KBr,
nmax/cm1): 3375, 3325, 3267 (NH2&NH), 1342 and 1153 (SO2); 1H
NMR (DMSO-d6) d ppm: 2.22 (s, 3H, CH3), 5.16 (s, 2H, -SO2CH2-), 7.12
(s, 2H, D2O exchangable, - SO2NH2), 7.16 (d, J¼ 8.8 Hz, 2H, Ar-H),
7.27e7.34 (m, 5H, Ar-H), 7.67 (d, J¼ 8.8 Hz, 2H, Ar-H), 7.71e7.75
(m, 4H, Ar-H)), 10.01 (s, 1H, D2O exchangable, -NH); 13C NMR
(DMSO-d6) d ppm: 21.42 (CH3), 52.57 (CH2), 112.66, 126.56, 127.12,
127.64, 128.36, 129.37, 129.97, 132.88, 135.04, 136.70, 137.66, 145.20,
147.63; Anal. Calcd. for C21H21N3O4S2 (443.54): C, 56.87; H, 4.77; N,
9.47; Found C, 57.14; H, 4.90; N, 9.68.
5.1.2.11. 4-[2-(1-(4-Fluorophenyl)-2-tosylethylidene)hydrazinyl]ben-
zenesulfonamide (4k). White crystals, (yield 66%), m. p.
238e240 C; IR (KBr, nmax/cm1): 3375, 3325, 3263 (NH2&NH),
1327 and 1153 (SO2); 1H NMR (DMSO-d6) d ppm: 2.23 (s, 3H, CH3),
5.16 (s, 2H, -SO2CH2-), 7.11 (s, 2H, D2O exchangable, - SO2NH2),
7.13e7.16 (m, 4H, Ar-H), 7.29 (d, J¼ 8.0 Hz, 2H, Ar-H), 7.67 (d,
J¼ 8.8 Hz, 2H, Ar-H), 7.71 (d, J¼ 8.2, 2H, Ar-H), 7.75e7.79 (m, 2H, Ar-
H), 9.98 (s, 1H, D2O exchangable, -NH); 13C NMR (DMSO-d6) d ppm:
21.40 (CH3), 52.62 (CH2), 112.65, 115.44, 127.64, 128.64, 129.85,
132.05, 134.23, 135.05, 136.62, 145.26, 147.59, 161.26, 163.70; ESI MS
m/z: 461 [M]þ, 462 [Mþ1]þ; Anal. Calcd. for C21H20FN3O4S2
(461.53): C, 54.65; H, 4.37; N, 9.10; Found C, 55.02; H, 4.51; N, 9.38.
5.1.2.12. 4-[2-(1-(4-Chlorophenyl)-2-tosylethylidene)hydrazinyl]ben-
zenesulfonamide (4l). White crystals, (yield 72%), m. p. 222e223 C;
IR (KBr, nmax/cm1): 3360, 3329, 3263 (NH2 & NH), 1334 and 1149
(SO2); 1H NMR (DMSO-d6) d ppm: 2.23 (s, 3H, CH3), 5.16 (s, 2H,
-SO2CH2-), 7.13 (s, 2H, D2O exchangable, - SO2NH2), 7.16 (d,
J¼ 8.8 Hz, 2H, Ar-H), 7.28 (d, J¼ 8.0 Hz, 2H, Ar-H), 7.35 (d, J¼ 8.6 Hz,
2H, Ar-H), 7.67e7.75 (m, 6H, Ar-H), 10.05 (s, 1H, D2O exchangable,
-NH); 13C NMR (DMSO-d6) d ppm: 21.26 (CH3), 52.40 (CH2), 112.83,
127.62, 128.14, 128.58, 130.02, 131.86, 133.26, 134.40, 135.82, 136.24,
145.89; Anal. Calcd. for C21H20ClN3O4S2 (477.98): C, 52.77; H, 4.22;
7.42; N, 8.79; Found C, 53.04; H, 4.07; N, 9.16.
5.1.2.13. 4-[2-(1-(4-Bromophenyl)-2-tosylethylidene)hydrazinyl]ben-
zenesulfonamide (4m). White crystals, (yield 81%), m. p.
248e249 C; IR (KBr, nmax/cm1): 3371, 3321, 3267 (NH2&NH), 1338
and 1153 (SO2); 1H NMR (DMSO-d6) d ppm: 2.23 (s, 3H, CH3), 5.15 (s,
2H, -SO2CH2-), 7.13 (s, 2H, D2O exchangable, - SO2NH2), 7.16 (d,
J¼ 8.8 Hz, 2H, Ar-H), 7.28 (d, J¼ 8.1 Hz, 2H, Ar-H), 7.48 (d, J¼ 8.6 Hz,
2H, Ar-H), 7.66e7.70 (m, 6H, Ar-H), 10.06 (s, 1H, D2O exchangable,
-NH); 13C NMR (DMSO-d6) d ppm: 21.26 (CH3), 52.33 (CH2), 112.85,121.89, 127.62, 128.39, 128.56, 130.02, 131.49, 131.93, 134.32, 135.71,
136.57, 145.92, 147.39; ESI MS m/z: 523 [Mþ1]þ, 524 [Mþ2]þ; Anal.
Calcd. for C21H20BrN3O4S2 (522.44): C, 48.28; H, 3.86; N, 8.04;
Found C, 48.69; H, 4.01; N, 8.37.
5.1.2.14. 4-[2-(1-(p-Tolyl)-2-tosylethylidene)hydrazinyl]benzene-
sulfonamide (4n). White crystals, (yield 65%), m. p. 224e225 C; IR
(KBr, nmax/cm1): 3383, 3325, 3275 (NH2&NH), 1342 and 1149
(SO2); 1H NMR (DMSO-d6) d ppm: 2.23 (s, 3H, CH3), 2.31 (s, 3H,
-CH3), 5.11 (s, 2H, -SO2CH2-), 7.11 (s, 2H, D2O exchangable, -
SO2NH2), 7.12e7.14 (m, 4H, Ar-H), 7.28 (d, J¼ 8.1 Hz, 2H, Ar-H), 7.63
(d, J¼ 8.2 Hz, 2H, Ar-H), 7.66 (d, J¼ 8.7 Hz, 2H, Ar-H), 7.71 (d,
J¼ 8.2 Hz, 2H, Ar-H), 9.89 (s, 1H, D2O exchangable, -NH); 13C NMR
(DMSO-d6) d ppm: 21.05, 21.25 (2 CH3), 52.55 (CH2), 112.59, 126.42,
127.58,128.49, 129.31,129.99,133.29,134.59, 135.92, 138.48, 145.79,
147.64; Anal. Calcd. for C22H23N3O4S2 (457.57): C, 57.75; H, 5.07; N,
9.18; Found C, 58.02; H, 4.95; N, 9.44.
5.1.2.15. 4-[2-(1-(4-Nitrophenyl)-2-tosylethylidene)hydrazinyl]ben-
zenesulfonamide (4o). Yellow crystals, (yield 84%), m. p.
241e243 C; IR (KBr, nmax/cm1): 3371, 3309, 3263 (NH2&NH), 1338
and 1149 (SO2); 1H NMR (DMSO-d6) d ppm: 2.20 (s, 3H, -CH3), 5.25
(s, 2H, -SO2CH2-), 7.17 (s, 2H, D2O exchangable, - SO2NH2), 7.24 (d,
J¼ 8.8 Hz, 2H, Ar-H), 7.28 (d, J¼ 8.0 Hz, 2H, Ar-H), 7.70e7.73 (m, 4H,
Ar-H), 7.98 (d, J¼ 9.0, 2H, Ar-H), 8.13 (d, J¼ 9.0 Hz, 2H, Ar-H), 10.36
(s, 1H, D2O exchangable, -NH); 13C NMR (DMSO-d6) d ppm: 21.35
(CH3), 52.29 (CH2), 113.31, 123.67, 127.33, 128.57, 129.91, 130.18,
130.93, 136.13, 136.44, 144.05, 145.45, 146.70, 146.97; Anal. Calcd.
for C21H20N4O6S2 (488.54): C, 51.63; H, 4.13; N, 11.47; Found C,
51.49; H, 4.29; N, 11.73.
5.1.2.16. 4-[2-(1-(Naphthalen-2-yl)-2-tosylethylidene)hydrazinyl]
benzenesulfonamide (4p). White crystals, (yield 66%), m. p.
226e227 C; IR (KBr, nmax/cm1): 3387, 3329, 3263 (NH2&NH),1323
and 1153 (SO2); 1H NMR (DMSO-d6) d ppm: 2.06 (s, 3H, -CH3), 5.28
(s, 2H, -SO2CH2-), 7.14 (s, 2H, D2O exchangable, - SO2NH2), 7.19 (d,
J¼ 8.0 Hz, 2H, Ar-H), 7.25 (d, J¼ 8.8 Hz, 2H, Ar-H), 7.49e7.52 (m, 2H,
Ar-H), 7.71 (d, J¼ 8.5 Hz, 4H, Ar-H), 7.78e7.80 (m, 1H, Ar-H), 7.83 (d,
J¼ 8.4 Hz, 1H, Ar-H), 7.86e7.88 (m, 1H, Ar-H), 7.99 (s, 1H, Ar-H),
8.04e8.07 (m, 1H, Ar-H), 10.13 (s, 1H, D2O exchangable, -NH); 13C
NMR (DMSO-d6) d ppm: 21.24 (CH3), 52.52 (CH2), 112.80, 113.78,
122.27, 124.13, 126.15, 126.66, 127.41, 127.95, 128.75, 129.77, 132.84,
133.13, 134.96, 136.69, 145.16, 147.69, 148.81; Anal. Calcd. for
C25H23N3O4S2 (493.6): C, 60.83; H, 4.70; N, 8.51; Found C, 61.18; H,
4.89; N, 8.24.
5.1.2.17. 4-(2-(1-(2-Thienyl)-2-tosylethylidene)hydrazinyl)benzene-
sulfonamide (4q). Grey crystals, (yield 75%), m. p. 231e233 C; IR
(KBr, nmax/cm1): 3360, 3332, 3267 (NH2&NH), 1338 and 1149
(SO2); 1H NMR (DMSO-d6) d ppm: 2.24 (s, 3H, -CH3), 5.12 (s, 2H, -
SO2CH2-), 7.02 (d, J¼ 8.7 Hz, 2H, Ar-H), 7.11 (s, 2H, D2O exchangable,
- SO2NH2), 7.19 (t, J¼ 4.4 Hz, 1H, H-thiophene), 7.27 (d, J¼ 8.1 Hz,
2H, Ar-H), 7.36 (d, J¼ 5.0 Hz, 1H, H-thiophene), 7.63 (d, J¼ 8.8 Hz,
2H, Ar-H), 7.70 (d, J¼ 8.1 Hz, 2H, Ar-H), 7.99 (d, J¼ 4.8 Hz, 1H, H-
thiophene), 9.99 (s, 1H, D2O exchangable, -NH); 13C NMR (DMSO-
d6) d ppm: 21.44 (CH3), 53.51 (CH2), 112.45, 126.93, 127.24, 127.65,
127.84, 128.77, 129.87, 129.98, 135.01, 136.58, 143.47, 145.32, 147.27;
Anal. Calcd. for C19H19N3O4S3 (449.57): C, 50.76; H, 4.26; N, 9.35;
Found C, 50.91; H, 4.50; N, 9.66.
5.2. Biological evaluation
5.2.1. Carbonic anhydrase inhibition
An Applied Photophysics stopped-flow instrument has been
used for assaying the CA catalysed CO2 hydration activity [18].
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cator, working at the absorbance maximum of 557 nm, with 20 mM
Hepes (pH 7.5) as buffer, and 20 mM Na2SO4 (for maintaining con-
stant the ionic strength), following the initial rates of the CA-
catalyzed CO2 hydration reaction for a period of 10e100 s. The
CO2 concentrations ranged from 1.7 to 17 mM for the determination
of the kinetic parameters and inhibition constants. For each in-
hibitor at least six traces of the initial 5e10% of the reaction have
been used for determining the initial velocity. The un-catalysed
rates were determined in the same manner and subtracted from
the total observed rates. Stock solutions of the inhibitor (0.1 mM)
were prepared in distilled-deionized water and dilutions up to
0.01 nM were done thereafter with the assay buffer. Inhibitor and
enzyme solutions were pre-incubated together for 15min at room
temperature prior to assay, in order to allow for the formation of
the E-I complex. The inhibition constants were obtained by non-
linear least-squares methods using PRISM 3 and the
ChengePrusoff equation, as reported earlier [29e32]. and repre-
sent the mean from at least three different determinations. All CA
isoforms were recombinant ones obtained in-house as reported
earlier [33e35].
5.2.2. In vitro cytotoxic assay
MCF-7 and MDA-MB-231 cancer cell lines were obtained from
the American wild type collection. Incubation of the cells was done
under hypoxic conditions of 5% CO2, all other procedures regarding
the assay was done using MTT assay as reported [36].
5.3. Computational studies
5LJT (hCA II) [21] and 5FL4 (hCA IX) [22] crystal structures were
prepared according to the Protein Preparation module in Maestro -
Schr€odinger suite, assigning bond orders, adding hydrogens, de-
leting water molecules, and optimizing H-bonding networks.
Finally, energy minimization with a root mean square deviation
(RMSD) value of 0.30 was applied using an Optimized Potentials for
Liquid Simulation (OPLS_2005) force field [37]. 3D ligand structures
were prepared by Maestro, evaluated for their ionization states at
pH 7.4± 0.5 with Epik OPLS-2005 force field in Macromodel was
used for energy minimization for a maximum number of 2500
conjugate gradient iterations and setting a convergence criterion of
0.05 kcalmol1Å1. Grids for docking were centered in the centroid
of the complexed ligand. Flexible docking studies were carried out
with the program Glide, using the standard precision (SP) mode,
turning on the sampling of ring conformation option and the post-
dockingminimization. The best scored docking poses were selected
and passed onto Prime for refinement with the VSGB continuum
solvent model [38].
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.ejmech.2018.04.016.
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